Rash News and Research

RSS

Shot may help reduce risk of shingles

Anyone who has had chickenpox or the chickenpox vaccine is at risk for the painful skin condition herpes zoster, more commonly known as shingles. Both diseases are caused by the varicella-zoster virus, which stays in the body after chickenpox clears and may reactivate later in life.

18 Feb 2018

FDA approves first treatment to reduce risk of NSCLC progression

The U.S. Food and Drug Administration today approved Imfinzi (durvalumab) for the treatment of patients with stage III non-small cell lung cancer (NSCLC) whose tumors are not able to be surgically removed (unresectable) and whose cancer has not progressed after treatment with chemotherapy and radiation (chemoradiation).

18 Feb 2018

New guidelines offer recommendations for assessment, management of immunotherapy side effects

Immunotherapy with immune checkpoint inhibitors is the first of a new generation of immunotherapy treatments, revolutionizing treatment for many different types of cancer. By unleashing the body's immune system to attack cancer, these treatments can send even the most hard-to-treat cancers into lasting remission.

15 Feb 2018

FDA approves new treatment for non-metastatic, castration-resistant prostate cancer

The U.S. Food and Drug Administration today approved Erleada (apalutamide) for the treatment of patients with prostate cancer that has not spread (non-metastatic), but that continues to grow despite treatment with hormone therapy (castration-resistant). This is the first FDA-approved treatment for non-metastatic, castration-resistant prostate cancer.

15 Feb 2018

Moffitt study identifies new drug target that may reduce GVHD risk

Stem cell transplants can cure patients with high-risk leukemia or lymphoma. Graft-versus-host disease is a potentially life-threatening side effect that occurs when the donor's immune cells attack the recipient's normal tissues.

5 Feb 2018

Measles outbreak alarms public health officials

According to the Public Health England (PHE) there are “large outbreaks” of measles in Europe that is cause for concern.

16 Jan 2018

The Virus That Causes Hand, Foot and Mouth Disease May Use Human Protein to Aid Infection

The human protein, prohibitin, may be used by the virus to enter motor neurons and cause the neurological complications of hand, foot and mouth disease.

12 Jan 2018

Dermatologist offers five tips to use petroleum jelly for skin care

The skin is the body's largest organ, so it's important to take good care of it. However, doing so doesn't necessarily mean breaking the bank, say dermatologists from the American Academy of Dermatology.

9 Jan 2018

Study: Living Lyme disease bacteria found months after antibiotic treatment

Bay Area Lyme Foundation, a leading sponsor of Lyme disease research in the US, today announced results of two papers published in the peer-reviewed journals PLOS ONE and American Journal of Pathology, that seem to support claims of lingering symptoms reported by many patients who have already received antibiotic treatment for the disease.

14 Dec 2017

First short-acting ‘follow-on’ insulin receives FDA approval to treat diabetes

The U.S. Food and Drug Administration today approved Admelog (insulin lispro injection), a short-acting insulin indicated to improve control in blood sugar levels in adults and pediatric patients aged 3 years and older with type 1 diabetes mellitus and adults with type 2 diabetes mellitus.

12 Dec 2017

New tests offer better chance for more accurate detection of Lyme disease

New tests to detect early Lyme disease - which is increasing beyond the summer months -could replace existing tests that often do not clearly identify the infection before health problems occur.

7 Dec 2017

FDA grants approval to first biosimilar for treatment of patients with breast, stomach cancers

The U.S. Food and Drug Administration today approved Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumors overexpress the HER2 gene (HER2+).

4 Dec 2017

Skin patch offers hope for people with peanut allergy

People who suffer from life-threatening peanut allergies may soon be able to cure their condition by wearing a skin patch, according to the findings of a phase 2 trial.

16 Nov 2017

FDA approves drug to treat pediatric, adult patients with rare Sly syndrome

The U.S. Food and Drug Administration today approved Mepsevii (vestronidase alfa-vjbk) to treat pediatric and adult patients with an inherited metabolic condition called mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome. MPS VII is an extremely rare, progressive condition that affects most tissues and organs.

15 Nov 2017

AstraZeneca’s new precision biologic gets FDA approval to treat severe eosinophilic asthma

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration has approved FASENRA (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

14 Nov 2017

FDA approves first targeted cancer treatment based on basket study

The US Food and Drug Administration has announced that it has approved the drug vemurafenib for the treatment of patients with BRAF V600-mutant Erdheim-Chester disease (ECD).

7 Nov 2017

FDA grants approval to first treatment for rare blood cancer

The U.S. Food and Drug Administration today expanded the approval of Zelboraf (vemurafenib) to include the treatment of certain adult patients with Erdheim-Chester Disease (ECD), a rare cancer of the blood.

7 Nov 2017

FDA approves new drug Zelboraf for Erdheim-Chester disease

The United States Food and Drugs Administration (FDA) has approved Zelboraf (vemurafenib), a drug for the treatment of adults with a are type of blood cancer called Erdheim-Chester Disease or ECD.

6 Nov 2017

New treatment reduces disease burden in patients with rare dermatologic condition

A new treatment for a rare and often incurable condition called dermatomyositis (DM) reduced the severity of the disease in patients whose DM was resistant to other therapies.

31 Oct 2017

University of Colorado’s second shingles vaccine approved by FDA

The Centers for Disease Control's Advisory Committee on Immunization Practices recommended new treatment practices Wednesday for shingles based on a vaccine initially developed at the University of Colorado Health Sciences Center, now the University of Colorado Anschutz Medical Campus.

28 Oct 2017